Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Reports indicate that the fragment does not appear to interact with hGH receptors, which may influence its distinct properties compared to the full hormone
There are various ways to administer peptides, like: Oral formulations Subcutaneous injections Topical creams or gels Nasal sprays Transdermal patches Peptide injections are the most common administration method
WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use
Initial Metabolic Changes (Days 1-14): While cellular-level metabolic changes begin within hours of the first AOD-9604 administration, noticeable subjective effects typically emerge within the first one to two weeks
At the cellular level, AOD-9604 exerts its primary effects through a complex mechanism involving beta-3 adrenergic receptors located on the surface of adipocytes (fat cells)
